metformin has been researched along with Akinetic-Rigid Variant of Huntington Disease in 8 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Metformin is a pleiotropic drug, modulating different targets such as AMPK, insulin signalling and many others." | 6.82 | Metformin to treat Huntington disease: A pleiotropic drug against a multi-system disorder. ( Casterá, F; Gómez-Escribano, AP; Herrero, MJ; Millán, JM; Peiró, C; Tortajada-Pérez, J; Trujillo-Del Río, C; Vázquez-Manrique, RP, 2022) |
| "Huntington disease is a neurodegenerative condition for which there is no cure to date." | 5.51 | Metformin treatment reduces motor and neuropsychiatric phenotypes in the zQ175 mouse model of Huntington disease. ( Cañada-Martínez, AJ; García-Gimeno, MA; Millán, JM; Sanchis, A; Sanz, P; Sequedo, MD; Vázquez-Manrique, RP, 2019) |
| "Metformin is a pleiotropic drug, modulating different targets such as AMPK, insulin signalling and many others." | 2.82 | Metformin to treat Huntington disease: A pleiotropic drug against a multi-system disorder. ( Casterá, F; Gómez-Escribano, AP; Herrero, MJ; Millán, JM; Peiró, C; Tortajada-Pérez, J; Trujillo-Del Río, C; Vázquez-Manrique, RP, 2022) |
| "Huntington disease is a neurodegenerative condition for which there is no cure to date." | 1.51 | Metformin treatment reduces motor and neuropsychiatric phenotypes in the zQ175 mouse model of Huntington disease. ( Cañada-Martínez, AJ; García-Gimeno, MA; Millán, JM; Sanchis, A; Sanz, P; Sequedo, MD; Vázquez-Manrique, RP, 2019) |
| " Long-term administration of metformin improved health and life span in mice." | 1.43 | Metformin Protects Cells from Mutant Huntingtin Toxicity Through Activation of AMPK and Modulation of Mitochondrial Dynamics. ( Anders, NM; Duan, W; Gu, H; Jiang, M; Jin, J; Peng, Q; Ren, T; Rudek, MA; Tao, M, 2016) |
| "Metformin treatment significantly prolonged the survival time of male HD mice at the 2mg/ml dose (20." | 1.34 | Metformin therapy in a transgenic mouse model of Huntington's disease. ( Buescher, JL; Carrier, RL; Funk, JA; Hoyt, KR; Ma, TC; Nash, AJ; Oatis, B, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 5 (62.50) | 24.3611 |
| 2020's | 2 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Trujillo-Del Río, C | 1 |
| Tortajada-Pérez, J | 1 |
| Gómez-Escribano, AP | 2 |
| Casterá, F | 1 |
| Peiró, C | 2 |
| Millán, JM | 3 |
| Herrero, MJ | 1 |
| Vázquez-Manrique, RP | 3 |
| Tang, BL | 1 |
| Hervás, D | 1 |
| Fornés-Ferrer, V | 1 |
| Sequedo, MD | 2 |
| Arnoux, I | 1 |
| Willam, M | 1 |
| Griesche, N | 1 |
| Krummeich, J | 1 |
| Watari, H | 1 |
| Offermann, N | 1 |
| Weber, S | 1 |
| Narayan Dey, P | 1 |
| Chen, C | 1 |
| Monteiro, O | 1 |
| Buettner, S | 1 |
| Meyer, K | 1 |
| Bano, D | 1 |
| Radyushkin, K | 1 |
| Langston, R | 1 |
| Lambert, JJ | 1 |
| Wanker, E | 1 |
| Methner, A | 1 |
| Krauss, S | 1 |
| Schweiger, S | 1 |
| Stroh, A | 1 |
| Pupyshev, AB | 1 |
| Korolenko, TA | 1 |
| Tikhonova, MA | 1 |
| Sanchis, A | 1 |
| García-Gimeno, MA | 1 |
| Cañada-Martínez, AJ | 1 |
| Sanz, P | 1 |
| Jin, J | 1 |
| Gu, H | 1 |
| Anders, NM | 1 |
| Ren, T | 1 |
| Jiang, M | 1 |
| Tao, M | 1 |
| Peng, Q | 1 |
| Rudek, MA | 1 |
| Duan, W | 1 |
| Ma, TC | 1 |
| Buescher, JL | 1 |
| Oatis, B | 1 |
| Funk, JA | 1 |
| Nash, AJ | 1 |
| Carrier, RL | 1 |
| Hoyt, KR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| "Randomized, Double-blind, Placebo-controlled Study to Assess the Effect of Metformin, an Activator of AMPK, on Cognitive Measures of Progression in Huntington's Disease Patients"[NCT04826692] | Phase 3 | 60 participants (Anticipated) | Interventional | 2021-12-10 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for metformin and Akinetic-Rigid Variant of Huntington Disease
| Article | Year |
|---|---|
Metformin to treat Huntington disease: A pleiotropic drug against a multi-system disorder.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Humans; Huntington Disease; Metformin; Neurodegene | 2022 |
Could metformin be therapeutically useful in Huntington's disease?
Topics: Animals; Humans; Huntington Disease; Hypoglycemic Agents; Metformin; Neurons; Neuroprotective Agents | 2020 |
[A Therapeutic Target for Inhibition of Neurodegeneration: Autophagy].
Topics: alpha-Synuclein; Alzheimer Disease; Amyloid beta-Peptides; Animals; Autophagy; Clinical Trials as To | 2016 |
5 other studies available for metformin and Akinetic-Rigid Variant of Huntington Disease
| Article | Year |
|---|---|
Metformin intake associates with better cognitive function in patients with Huntington's disease.
Topics: Adult; Aged; Case-Control Studies; Cognition; Cross-Sectional Studies; Female; Humans; Huntington Di | 2017 |
Metformin reverses early cortical network dysfunction and behavior changes in Huntington's disease.
Topics: Animals; Astrocytes; Behavior, Animal; Caenorhabditis elegans; Calcium; Cell Respiration; Cerebral C | 2018 |
Metformin treatment reduces motor and neuropsychiatric phenotypes in the zQ175 mouse model of Huntington disease.
Topics: AMP-Activated Protein Kinases; Animals; Brain; Caenorhabditis elegans; Disease Models, Animal; Human | 2019 |
Metformin Protects Cells from Mutant Huntingtin Toxicity Through Activation of AMPK and Modulation of Mitochondrial Dynamics.
Topics: AMP-Activated Protein Kinases; Animals; Disease Models, Animal; Enzyme Activation; Huntingtin Protei | 2016 |
Metformin therapy in a transgenic mouse model of Huntington's disease.
Topics: Age Factors; AMP-Activated Protein Kinases; Animals; Behavior, Animal; Blood Glucose; Disease Models | 2007 |